drugset
drugset / Trial / NCT02073916

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

NCT02073916 ↗

Phase 1 Completed 24 enrolled Jenny C. Chang, MD The Methodist Hospital Research Institute · collab
NaSingle-groupOpen-labelTreatment

Summary

This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.

Timeline

Start
2013-10
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Abraxane Small molecule — —
Subject Lapatinib Small molecule — Oral
Subject Trastuzumab emtansine Other / unclassified — —

Indications

breast cancer